RxDoctor Payments Data

Pardeep Kumari, MD

Infectious Disease · Pensacola, FLNPI 1083697320

Payments from drug & device makers

$3,418in general payments, 2019–2025

Across 202 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$926
  • Viiv Healthcare Company$461
  • Merck$437
  • AbbVie$414
  • Paratek Pharmaceuticals, Inc.$246
  • Melinta Therapeutics, LLC$145
  • plus $790 from 17 others

What the payments were for

  • Food & beverage$3,418100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,418 in reported general payments places this provider in the 70th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$3,538,996
Medicare patients
2,051
Services billed
242,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabenuvaCabotegravir/Rilpivirine21$139,156
StribildElviteg/Cob/Emtri/Tenofo Disop25$117,071
DovatoDolutegravir Sodium/Lamivudine23$77,882
GenvoyaElviteg/Cob/Emtri/Tenof Alafen15$63,437
JulucaDolutegravir/Rilpivirine14$56,985
BiktarvyBictegrav/Emtricit/Tenofov Ala11$42,741
Daptomycin88$40,935
Vancomycin Hcl315$38,747
Cefepime Hcl113$21,372
Meropenem202$20,281
SantylCollagenase Clostridium Hist.31$16,061
Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod84$12,242
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam63$6,866
CeftriaxoneCeftriaxone Sodium108$5,994
Sodium Chloride0.9 % Sodium Chloride258$4,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyCabenuva, Dovato, Juluca$461$274,02358 claims
Smith+NephewSantyl$139$16,06131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →